JP3378847B2 - Crystals of L-ascorbic acid-2-phosphate sodium salt - Google Patents

Crystals of L-ascorbic acid-2-phosphate sodium salt

Info

Publication number
JP3378847B2
JP3378847B2 JP2000050913A JP2000050913A JP3378847B2 JP 3378847 B2 JP3378847 B2 JP 3378847B2 JP 2000050913 A JP2000050913 A JP 2000050913A JP 2000050913 A JP2000050913 A JP 2000050913A JP 3378847 B2 JP3378847 B2 JP 3378847B2
Authority
JP
Japan
Prior art keywords
salt
solution
crystals
asa2p
ascorbic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000050913A
Other languages
Japanese (ja)
Other versions
JP2000309596A (en
Inventor
照美 岡田
道夫 塩見
英治 高崎
Original Assignee
協和醗酵工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP13153698A external-priority patent/JP3117949B2/en
Application filed by 協和醗酵工業株式会社 filed Critical 協和醗酵工業株式会社
Priority to JP2000050913A priority Critical patent/JP3378847B2/en
Publication of JP2000309596A publication Critical patent/JP2000309596A/en
Application granted granted Critical
Publication of JP3378847B2 publication Critical patent/JP3378847B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

【発明の詳細な説明】 【0001】 【発明の属する技術分野】本発明は、L−アスコルビン
酸−2−リン酸(以下、AsA2Pと略記する。)のナ
トリウム塩(以下、Na塩と略記する。)結晶に関す
る。AsA2PNa塩の結晶は、アスコルビン酸の安定
化誘導体として有用であり、医薬品、食品、化粧品その
他各種の工業分野に使用され得る。 【0002】 【従来の技術】従来、AsA2Pに関する報告は数多く
知られている。たとえば、ビタミン(Vitamin
s;Japan)41巻(1970年)の387〜39
8ページにはアスコルビン酸リン酸エステルの化学と応
用について書かれており、とくに390ページにはアス
コルビン酸−3−リン酸エステルのマグネシウム塩、ナ
トリウム塩、カルシウム塩の性質が書かれている。アス
コルビン酸−3−リン酸ナトリウム塩の性質については
無色粉末で結晶しがたいと記載されている。なお、この
文献のアスコルビン酸−3−リン酸は、ビタミン51巻
(1985年)の185ぺージでAsA2Pに訂正され
ている。 【0003】その他、AsA2Pの精製法として、活性
炭を用いる方法(特開昭59−51293、特開昭59
−106494)、強酸性陽イオン交換樹脂を用いる方
法、強塩基性陰イオン交換樹脂を用いる方法(特公昭4
5−4497)、弱塩基性または中塩基性陰イオン交換
樹脂を用いる方法(特開昭62−30791)、弱酸型
キレート樹脂を用いる方法(特開昭62−10309
6)などの方法が知られている。 【0004】特開昭59−51293号公報には、目的
物である精製後のAsA2Pを脱カチオン処理した後、
塩の形にするのが好ましいと書かれている。塩の形とし
て、マグネシウム塩、カルシウム塩、ナトリウム塩、カ
リウム塩などが記されている。さらに、このようにして
得られる目的物を含有する液を通常おこなわれる濃縮工
程、晶出工程に付す、とも書かれているが、実施例はす
べてマグネシウム塩に関するものばかりで、ナトリウム
塩の結晶については書かれていない。また、本発明者は
この公報記載の方法でナトリウム塩の結晶を得ようと試
みたが、結晶はできずアメ状のものができたにすぎなか
った。 【0005】 【発明が解決しようとする課題】一般的にAsA2Pは
Mg塩の形で実用化されているが、その精製過程、製品
の使用の際に以下に述べる点が問題となっている。 AsA2PMg塩は、非晶質であるため晶析によっ
て高純度のAsA2PMg塩を得るのは困難である。特
に、反応原料の未反応物及び副生物として生成するリン
化合物が不溶性のMg塩を形成して精製を困難にしてい
る。 AsA2PMg塩は、非晶質のため、含水率、溶媒
残留率が高く、また、乾燥による付着水分や溶媒の除去
も容易ではない。 AsA2PMg塩は水に対して溶解速度が遅く、ア
メ状になりやすい。そのため工業的実用濃度に溶解する
には、溶解時の分散方法を工夫する必要がある。 AsA2PMg塩を用いる場合、水が存在する系で
は経時的に徐々に着色してしまう。 【0006】そこで安定で取り扱い易い形態のAsA2
Pの開発が望まれている。 【0007】 【課題を解決するための手段】本発明によれば、安定で
取り扱い易く、高純度のAsA2Pが、新規なAsA2
PNa塩の結晶として提供される。また本発明によれ
ば、C6 6 9 PNa3 ・1/2H2Oの分子式で示され
るAsA2PNa塩の結晶が提供される。 【0008】また本発明によれば、Cu−K2 線を用い
る粉末X線回折で、面間隔d(Å)および比較強
度[()内に%で表す]の解析パターンが、12.8
(9)、12.017(100)、7.893(3)、
7.589(48)、5.921(7)、5.368
(5)、5.049(18)、4.883(13)、
4.691(45)、4.514(10)、4.469
(10)、4.055(25)、3.751(13)、
3.637(28)、3.594(25)、3.538
(15)、3.367(12)、3.311(29)、
3.281(31)、2.882(9)、2.807
(19)、2.765(51)、2.724(53)、
2.645(14)、2.509(11)、2.472
(11)、2.375(10)、2.276(21)、
2.189(9)、2.108(9)、1.91
(7)、1.906(4)、1.839(8)、である
L−アスコルビン酸−2−リン酸ナトリウム塩の結晶が
提供される。 【0009】また本発明によれば、AsA2Pを含有す
る溶液を、水酸化ナトリウムでpH8〜10に調整し、
この溶液を40〜80℃の温度で加熱・還流しながら、
炭素数5以下の低級脂肪族アルコール、炭素数5以下の
脂肪族飽和ケトンおよび環状エーテルから選ばれる有機
溶媒を溶液中の濃度が30〜80%(v/v)となるよ
うに4〜7時間かけて該溶液に徐々に添加した後、30
℃以下の温度で放置して得られるAsA2PNa塩の結
晶が提供される。 【0010】また本発明によればAsA2Pの金属塩あ
るいはアルカリ土類金属塩を含有する溶液を脱カチオン
処理した後、水酸化ナトリウムでpH8〜10に調整
し、この溶液を40〜80℃の温度で加熱・還流しなが
ら炭素数5以下の低級脂肪族アルコール、炭素数5以下
の脂肪族飽和ケトンおよび環状エーテルから選ばれる有
機溶媒を溶液中の濃度が30〜80%(v/v)となる
ように4〜7時間かけて該溶液に徐々に添加した後、3
0℃以下の温度で放置して得られるAsA2PNa塩の
結晶が提供される。 【0011】 〔発明の詳細な説明〕本発明のAsA2PNa塩の結晶
の物性を以下に示す。 (1) 元素分析値 【0012】 【表1】【0013】(2) 分子量 ; 331.0 (3) X線回析図 ; Cu−K2 線を用い粉末X
線回折法で測定して得られたX線回折図形を第1図に示
す。なお、図中の数字は第2表の番号に対応する。比較
強度は、図中のピーク2を100として表わしている。 【0014】 【表2】 【0015】(4) 赤外線吸収スペクトル ; KB
r錠剤法で測定した赤外線吸収スペクトルを第2図に示
す。 (5)溶剤に対する溶解性 ; 水には溶け易いが、低
級アルコール類、ケトン類には溶けにくい。エーテルに
はほとんど溶けない。第3図にNa塩、Mg塩の比較溶
解速度を示す。 【0016】(6) 塩基性、酸性、中性の区別 ;
弱塩基性 (7) 物質の色 ; 無色透明 (8) 結晶の形 ; 通常は柱状晶になる。 【0017】本発明で用いる出発溶液はAsA2Pを含
有する液であればAsA2P溶液、AsA2Pの金属塩
溶液もしくはアルカリ土類金属塩溶液などいずれも対象
とすることができる。例えば、アスコルビン酸とリン酸
供与体とから酵素あるいは微生物の作用によって生成し
たAsA2P含有液は好適に利用できる。金属塩として
はカリウム塩、アルカリ土類金属塩としてはマグネシウ
ム塩、カルシウム塩があげられる。 【0018】AsA2Pが塩の形である場合、あるいは
AsA2P含有液がアルカリ金属、アルカリ土類金属等
の金属イオンを含有する場合はその水溶液を適当なイオ
ン交換樹脂で処理して脱カチオンすることが望ましい。
AsA2Pをイオン交換樹脂に吸着させ、0.1〜2N
の希塩酸で溶出した後、水酸化ナトリウムでpH調整が
行われる。 【0019】水酸化ナトリウムによるpH調整は、通常
5〜15Nの水酸化ナトリウム水溶液で行われる。pH
調整後の溶液中のAsA2P濃度は30〜100g/
l、好ましくは50〜80g/lであり、必要に応じて
水で希釈し、あるいは減圧濃縮等によって濃縮される。
次いで該溶液を40〜80℃好ましくは50〜70℃の
温度で加熱還流しながら有機溶媒をその濃度が30〜8
0%(v/v)になるように4〜7時間かけてゆっくり
添加して結晶を晶出させる。必要に応じてさらに加熱還
流を2〜10時間継続する。 【0020】用いられる有機溶媒としてはメタノール、
エタノール等の炭素数5以下の低級脂肪族アルコール、
アセトンなどの炭素数5以下の脂肪族飽和ケトン類、テ
トテヒドロフラン等の環状エーテルが例示される。これ
らの有機溶媒は、単独でも混合しても用いられる。加
熱、還流後30℃以下の温度に放置すると晶出した結晶
が生長、熟成する。結晶はろ過によって単離し、前記有
機溶媒で洗浄した後、真空乾燥等の処理によって高純度
の白色結晶状AsA2PNa塩が得られる。 【0021】本発明方法によればAsA2P生成反応の
反応液中の未反応リン化合物はナトリウムと溶解度の高
い塩を形成するので製品への混入量が少なく、結晶の晶
出母液からの分離性が良く、再結晶操作の回数が少なく
てすむ。また得られる結晶は含水率が少なく、付着水
分、溶媒の除去が容易で、溶解速度が速い。 【0022】本発明の態様を実施例によって説明する。 【0023】 【実施例】実施例1 シュードモナス・アゾトコリガンス ATCC 124
17をポリペプトン10g/l、肉エキス7g/l、酵
母エキス5g/lおよびNaCl 3g/lを含むpH
7.2に調整した培地(以下、KM102培地と略
す。)30mlに植菌し、30℃で20時間培養した。
ついでKM102培地300mlに上記で得られた種培
養液12mlを植菌し、30℃で、20時間培養した。
得られた培養液を10,000×gにて10分間遠心分
離し、湿菌体11.8gを得て、−20℃にて凍結保存
した。凍結保存菌体50mg/ml(湿菌体重量)を含
むアスコルビン酸200mM、ピロリン酸カリウム20
0mM、酢酸ナトリウム緩衝液(pH 4.0)100
mM、ナイミーンS−215(日本油脂社製)4g/
l、キシレン10ml/lの組成の反応液50mlを、
マグネチック・スターラーにて100rpmで攪拌しつ
つ、水酸化ナトリウムでpHを4.0付近に、温度を4
0℃に保って36時間反応させた。得られた反応液(A
sA2P 30g/l含む。)1リットルを徐菌過し、
液をプロライトA100(中塩基性陰イオン交換樹脂、
プロライト・インターナショナル社製)1リットルを充
填した塔に通液した。吸着したAsA2Pを1N希塩酸
で溶離した。 【0024】溶離により得られた溶液を10N水酸化ナ
トリウム水溶液でpH9.5に調整した。この液のAs
A2Pの濃度を80g/lに減圧濃縮後0.45ミクロ
ンのミリポアフィルターを用いて過した。液を60℃に
加熱還流、攪拌しながら、メタノール900mlを約6
時間かけてゆっくり加え、その後3時間加熱還流を継続
した。30℃以下で一晩放置した。生じた結晶を過し、
メタノールで洗浄した。次いで40℃で一夜真空乾燥し
て目的とするAsA2PNa塩の結晶の精製品21.4
g(収率71%)を得た。得られた精製品の製品分析値
を第3表に示す。 【0025】実施例2 実施例1と同様な方法によって得られたAsA2P 2
0.0g/lを含有する反応液を1N水酸化ナトリウム
水溶液でpH4.0に調整し、粉末活性炭4gを添加
し、50℃で30分間放置して脱色後過した。液を再度
1N水酸化ナトリウム水溶液でpH9.5に調整し、A
sA2P 80g/lになるよう減圧濃縮した。濃縮液
300mlを60℃に加熱還流攪拌しながらアセトン6
00mlを6時間かけてゆっくり加え、さらに3時間還
流した後5℃で3時間放置した。生じた結晶を過し、ア
セトンで洗浄した。次いで40℃で一夜真空乾燥し、目
的とするAsA2PNaの結晶の精製品16.5g(収
率80%)を得た。 【0026】実施例3 AsA2PMg塩(未精製品)50.0gを精製水1リ
ットルに溶解した。この溶液をダイヤイオンSK−1B
(強酸性陽イオン交換樹脂,三菱化成社製)500ml
を充填した塔に通液し、脱カチオンした。流出液を1N
水酸化ナトリウム水溶液でpH9.5に調整し、粉末活
性炭5gで脱色後過した。液を実施例1と同様に晶析、
乾燥し目的とするAsA2PNa塩の結晶の精製品4
2.5g(収率85%)を得た。得られた精製品の製品
分析値を第3表に示す。 【0027】比較例 実施例1と同様な方法によって得られたAsA2P 2
0.0g/lを含有する1N希塩酸溶液を1N水酸化マ
グネシウム溶液でpH8に調整した。粉末活性炭で脱色
過し、液のAsA2Pの濃度を50g/lになる迄減圧
濃縮し、濃縮液を60℃に加熱攪拌しながらこれにメタ
ノール900mlを6時間かけてゆっくり添加した。さ
らに3時間還流後冷却し一夜30℃以下で放置し生じた
沈殿物を過し、乾燥してAsA2PMg塩の精製品2
2.5g(収率75%)を得た。得られた精製品の製品
分析値を第3表に示す。 【0028】 【表3】 【0029】 【発明の効果】本発明によりAsA2PNa塩の結晶
が、高純度、高収率で提供される。
Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a sodium salt of L-ascorbic acid-2-phosphate (hereinafter abbreviated as AsA2P) (hereinafter abbreviated as Na salt). .) Regarding crystals. Crystals of AsA2PNa salt are useful as stabilized derivatives of ascorbic acid, and can be used in pharmaceuticals, foods, cosmetics, and various other industrial fields. [0002] Conventionally, many reports on AsA2P have been known. For example, vitamins (Vitamin
s; Japan) 41 (1970) 387-39
Page 8 describes the chemistry and application of ascorbic acid phosphate, and page 390 describes the properties of magnesium, sodium and calcium salts of ascorbic acid-3-phosphate. The property of sodium ascorbic acid-3-phosphate is described as a colorless powder which is difficult to crystallize. In addition, ascorbic acid-3-phosphate in this document has been corrected to AsA2P in 185 pages of Vitamin 51 (1985). In addition, as a method for purifying AsA2P, a method using activated carbon (JP-A-59-51293, JP-A-59-59293).
-106494), a method using a strongly acidic cation exchange resin, and a method using a strongly basic anion exchange resin (Japanese Patent Publication No. Sho 4).
5-4497), a method using a weakly basic or medium basic anion exchange resin (JP-A-62-30791), and a method using a weak acid-type chelate resin (JP-A-62-10309).
Methods such as 6) are known. JP-A-59-51293 discloses that after purifying AsA2P, which is an object, after decationization,
It is stated that salt form is preferred. As the salt form, magnesium salt, calcium salt, sodium salt, potassium salt and the like are described. Further, it is described that the solution containing the target substance obtained in this manner is subjected to a concentration step and a crystallization step which are usually performed, but all the examples are directed to magnesium salts, and to the sodium salt crystals. Is not written. In addition, the present inventor tried to obtain sodium salt crystals by the method described in this publication, but could not produce crystals but merely produced candy. [0005] Generally, AsA2P is put into practical use in the form of Mg salt, but there are problems in the purification process and the use of products as described below. Since AsA2PMg salt is amorphous, it is difficult to obtain high purity AsA2PMg salt by crystallization. In particular, the unreacted reaction raw material and the phosphorus compound generated as a by-product form an insoluble Mg salt, making purification difficult. Since AsA2PMg salt is amorphous, it has a high water content and a high solvent residual ratio, and it is not easy to remove adhering moisture and solvent by drying. AsA2PMg salt has a slow dissolution rate in water and tends to be candy-like. Therefore, in order to dissolve it in an industrially practical concentration, it is necessary to devise a dispersion method at the time of dissolution. In the case where AsA2PMg salt is used, in a system in which water is present, the color gradually increases over time. Accordingly, a stable and easy-to-handle AsA2
The development of P is desired. [0007] According to the present invention, a stable and easy-to-handle, high-purity AsA2P is converted to a novel AsA2P.
Provided as crystals of the PNa salt. Further, according to the present invention, there is provided a crystal of an AsA2PNa salt represented by the molecular formula of C 6 H 6 O 9 PNa 3 .1 / 2H 2 O. According to the present invention, the analysis pattern of the interplanar spacing d (2) and the comparative intensity [expressed in% in ()] is 12.8 in the powder X-ray diffraction using Cu-K 2 ray.
(9), 12.017 (100), 7.893 (3),
7.589 (48), 5.921 (7), 5.368
(5) 5.049 (18), 4.883 (13),
4.691 (45), 4.514 (10), 4.469
(10), 4.055 (25), 3.751 (13),
3.637 (28), 3.594 (25), 3.538
(15), 3.33 (12), 3.311 (29),
3.281 (31), 2.882 (9), 2.807
(19), 2.765 (51), 2.724 (53),
2.645 (14), 2.509 (11), 2.472
(11), 2.375 (10), 2.276 (21),
2.189 (9), 2.108 (9), 1.91
(7) A crystal of sodium L-ascorbic acid-2-phosphate, which is 1.906 (4), 1.839 (8), is provided. According to the present invention, the solution containing AsA2P is adjusted to pH 8 to 10 with sodium hydroxide,
While heating and refluxing this solution at a temperature of 40 to 80 ° C,
An organic solvent selected from a lower aliphatic alcohol having 5 or less carbon atoms, an aliphatic saturated ketone having 5 or less carbon atoms and a cyclic ether is used for 4 to 7 hours so that the concentration in the solution becomes 30 to 80% (v / v). And slowly added to the solution,
There is provided a crystal of an AsA2PNa salt obtained by standing at a temperature of not more than ° C. Further, according to the present invention, a solution containing a metal salt or an alkaline earth metal salt of AsA2P is decationized, adjusted to pH 8 to 10 with sodium hydroxide, and the solution is heated to a temperature of 40 to 80 ° C. The concentration of an organic solvent selected from a lower aliphatic alcohol having 5 or less carbon atoms, an aliphatic saturated ketone having 5 or less carbon atoms and a cyclic ether in a solution becomes 30 to 80% (v / v) while heating and refluxing. After slowly adding to the solution over 4 to 7 hours,
There is provided a crystal of an AsA2PNa salt obtained by standing at a temperature of 0 ° C. or lower. DETAILED DESCRIPTION OF THE INVENTION The physical properties of the crystals of the AsA2PNa salt of the present invention are shown below. (1) Elemental analysis values [Table 1] (2) molecular weight: 331.0 (3) X-ray diffraction diagram: powder X using Cu-K 2 ray
The X-ray diffraction pattern obtained by the X-ray diffraction method is shown in FIG. The numbers in the figure correspond to the numbers in Table 2. The comparative intensity is represented with the peak 2 in the figure as 100. [Table 2] (4) Infrared absorption spectrum: KB
FIG. 2 shows the infrared absorption spectrum measured by the r-tablet method. (5) Solubility in solvents; easily soluble in water, but hardly soluble in lower alcohols and ketones. Hardly soluble in ether. FIG. 3 shows the comparative dissolution rates of Na salt and Mg salt. (6) Basic, acidic and neutral distinctions;
Weak basic (7) Color of substance; colorless and transparent (8) Crystal form; usually columnar. The starting solution used in the present invention may be any solution containing AsA2P, such as a AsA2P solution, a metal salt solution of AsA2P or an alkaline earth metal salt solution. For example, an AsA2P-containing liquid produced by the action of an enzyme or a microorganism from ascorbic acid and a phosphate donor can be suitably used. Metal salts include potassium salts, and alkaline earth metal salts include magnesium salts and calcium salts. When AsA2P is in the form of a salt, or when the AsA2P-containing liquid contains a metal ion such as an alkali metal or an alkaline earth metal, the aqueous solution can be treated with an appropriate ion exchange resin to decationize. desirable.
AsA2P is adsorbed on an ion exchange resin, and 0.1-2N
After elution with dilute hydrochloric acid, the pH is adjusted with sodium hydroxide. The pH adjustment with sodium hydroxide is usually performed with a 5 to 15N aqueous sodium hydroxide solution. pH
The concentration of AsA2P in the adjusted solution is 30 to 100 g /
l, preferably 50 to 80 g / l, and if necessary, it is diluted with water or concentrated by vacuum concentration or the like.
Then, the solution is heated to reflux at a temperature of 40 to 80 ° C., preferably 50 to 70 ° C., and the organic solvent is concentrated at 30 to 8%.
Crystallize by slow addition over 4-7 hours to 0% (v / v). If necessary, heat reflux is continued for 2 to 10 hours. The organic solvent used is methanol,
A lower aliphatic alcohol having 5 or less carbon atoms such as ethanol,
Examples thereof include aliphatic saturated ketones having 5 or less carbon atoms such as acetone, and cyclic ethers such as tetotehydrofuran. These organic solvents may be used alone or in combination. When left at a temperature of 30 ° C. or less after heating and reflux, the crystallized crystals grow and mature. The crystals are isolated by filtration, washed with the organic solvent, and then dried in a vacuum or the like to obtain a high-purity white crystalline AsA2PNa salt. According to the method of the present invention, the unreacted phosphorus compound in the reaction solution of the AsA2P formation reaction forms a salt with high solubility with sodium, so that the amount of the unreacted phosphorus compound mixed into the product is small, and the separability of crystals from the crystallization mother liquor is low. Good, the number of recrystallization operations is small. The obtained crystals have a low water content, easy removal of adhering moisture and solvent, and high dissolution rate. The embodiments of the present invention will be described by way of examples. EXAMPLES Example 1 Pseudomonas azotocolligans ATCC 124
17 at pH containing polypeptone 10 g / l, meat extract 7 g / l, yeast extract 5 g / l and NaCl 3 g / l
The cells were inoculated into 30 ml of a medium adjusted to 7.2 (hereinafter abbreviated as KM102 medium) and cultured at 30 ° C. for 20 hours.
Then, 12 ml of the seed culture obtained above was inoculated into 300 ml of KM102 medium, and cultured at 30 ° C. for 20 hours.
The obtained culture was centrifuged at 10,000 × g for 10 minutes to obtain 11.8 g of wet cells, which were stored frozen at −20 ° C. 200 mM ascorbic acid, potassium pyrophosphate 20 containing 50 mg / ml (wet cell weight) of cryopreserved cells
0 mM, sodium acetate buffer (pH 4.0) 100
mM, Nimeen S-215 (manufactured by NOF Corporation) 4 g /
l, 50 ml of a reaction solution having a composition of xylene 10 ml / l,
While stirring at 100 rpm with a magnetic stirrer, the pH was adjusted to around 4.0 with sodium hydroxide,
The reaction was maintained at 0 ° C. for 36 hours. The obtained reaction solution (A
Contains 30 g / l of sA2P. ) Slowly sterilize 1 liter,
The solution was treated with Prolite A100 (medium basic anion exchange resin,
The solution was passed through a tower filled with 1 liter (prolight international). The adsorbed AsA2P was eluted with 1N diluted hydrochloric acid. The solution obtained by the elution was adjusted to pH 9.5 with a 10N aqueous sodium hydroxide solution. As of this liquid
After concentration under reduced pressure to a concentration of A2P of 80 g / l, the mixture was passed through a 0.45 micron Millipore filter. The solution was heated to reflux at 60 ° C., and while stirring, 900 ml of methanol was added for about 6 hours.
The mixture was added slowly over a period of time, and then heated under reflux for 3 hours. It was left overnight at 30 ° C. or lower. Have the resulting crystals,
Washed with methanol. Then, vacuum drying at 40 ° C. overnight is carried out to purify the desired crystal of AsA2PNa salt 21.4.
g (yield 71%) was obtained. Table 3 shows the product analysis values of the obtained purified product. Example 2 AsA2P 2 obtained by the same method as in Example 1
The reaction solution containing 0.0 g / l was adjusted to pH 4.0 with a 1N aqueous sodium hydroxide solution, and 4 g of powdered activated carbon was added. The solution was adjusted to pH 9.5 again with a 1N aqueous solution of sodium hydroxide.
It was concentrated under reduced pressure to 80 g / l of sA2P. Heat 300 ml of the concentrated solution to 60 ° C. while stirring under reflux, acetone 6
00 ml was added slowly over 6 hours, refluxed for 3 hours, and left at 5 ° C. for 3 hours. The resulting crystals were collected and washed with acetone. Then, vacuum drying was carried out at 40 ° C. overnight to obtain 16.5 g (yield: 80%) of the purified AsA2PNa crystal. Example 3 50.0 g of AsA2PMg salt (unrefined product) was dissolved in 1 liter of purified water. This solution was added to Diaion SK-1B.
(Strongly acidic cation exchange resin, manufactured by Mitsubishi Kasei Corporation) 500ml
The solution was passed through a column packed with and decationized. 1N effluent
The pH was adjusted to 9.5 with an aqueous sodium hydroxide solution, and the mixture was decolorized with 5 g of powdered activated carbon and passed through. The liquid was crystallized as in Example 1,
Purified purified crystals of the desired AsA2PNa salt 4
2.5 g (85% yield) were obtained. Table 3 shows the product analysis values of the obtained purified product. Comparative Example AsA2P 2 obtained by the same method as in Example 1.
A 1N dilute hydrochloric acid solution containing 0.0 g / l was adjusted to pH 8 with a 1N magnesium hydroxide solution. The solution was decolorized with activated carbon powder, concentrated under reduced pressure until the concentration of AsA2P in the solution became 50 g / l, and 900 ml of methanol was slowly added thereto over 6 hours while heating and stirring the concentrated solution at 60 ° C. After further refluxing for 3 hours, the mixture was cooled, left standing at 30 ° C. or less overnight, and the resulting precipitate was removed and dried to purify AsA2PMg salt purified product 2
2.5 g (75% yield) were obtained. Table 3 shows the product analysis values of the obtained purified product. [Table 3] According to the present invention, crystals of AsA2PNa salt are provided with high purity and high yield.

【図面の簡単な説明】 【図1】本発明のAsA2PNa塩結晶の粉末X線回折
図形である。縦軸は回折強度、横軸は回折角度を示す。 【図2】AsA2PNa塩結晶の赤外線吸収スペクトル
である。縦軸は透過率、横軸は波数を示す。 【図3】AsA2PNa塩結晶、AsA2PMg塩の溶
解速度を比較したものである。図中、1はAsA2PN
a塩結晶、2はAsA2PMg塩を示す。縦軸は、上澄
中のAsA2P濃度、横軸は攪拌溶解時間を示す 【図4】AsA2PNa塩結晶の写真(200倍)であ
る。
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a powder X-ray diffraction pattern of the AsA2PNa salt crystal of the present invention. The vertical axis indicates the diffraction intensity, and the horizontal axis indicates the diffraction angle. FIG. 2 is an infrared absorption spectrum of an AsA2PNa salt crystal. The vertical axis shows the transmittance, and the horizontal axis shows the wave number. FIG. 3 is a comparison of the dissolution rates of AsA2PNa salt crystals and AsA2PMg salts. In the figure, 1 is AsA2PN
a salt crystal, 2 represents AsA2PMg salt. The vertical axis indicates the concentration of AsA2P in the supernatant, and the horizontal axis indicates the stirring and dissolution time. FIG. 4 is a photograph (200 times) of the AsA2PNa salt crystal.

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 平2−131494(JP,A) “BIOCHEMICAL MEDI CINE”1978,第19巻,P.118〜126 (58)調査した分野(Int.Cl.7,DB名) C07F 9/655 CA(STN) REGISTRY(STN)──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-2-131494 (JP, A) "BIOCHEMICAL MEDI CINE" 1978, Vol. 118-126 (58) Field surveyed (Int. Cl. 7 , DB name) C07F 9/655 CA (STN) REGISTRY (STN)

Claims (1)

(57)【特許請求の範囲】 【請求項1】 L−アスコルビン酸−2−リン酸ナトリ
ウム塩の結晶〔但し、Cu−K 2 線を用いる粉末X線回
折で、面間隔d(Å)および比較強度[()内に%で表
す]の解析パターンが、12.8(9)、12.017
(100)、7.893(3)、7.589(48)、
5.921(7)、5.368(5)、5.049(1
8)、4.883(13)、4.691(45)、4.
514(10)、4.469(10)、4.055(2
5)、3.751(13)、3.637(28)、3.
594(25)、3.538(15)、3.367(1
2)、3.311(29)、3.281(31)、2.
882(9)、2.807(19)、2.765(5
1)、2.724(53)、2.645(14)、2.
509(11)、2.472(11)、2.375(1
0)、2.276(21)、2.189(9)、2.1
08(9)、1.91(7)、1.906(4)、1.
839(8)、であるL−アスコルビン酸−2−リン酸
ナトリウム塩の結晶を除く〕
(57) [Claims 1] Crystals of sodium salt of L-ascorbic acid-2-phosphate [however, powder X-ray diffraction using Cu-K 2 radiation]
The distance between d (d) and the comparative strength [
Analysis pattern is 12.8 (9), 12.017
(100), 7.893 (3), 7.589 (48),
5.921 (7), 5.368 (5), 5.049 (1
8), 4.883 (13), 4.691 (45), 4.
514 (10), 4.469 (10), 4.055 (2
5) 3.751 (13), 3.637 (28), 3.
594 (25), 3.538 (15), 3.367 (1
2) 3.311 (29), 3.281 (31), 2.
882 (9), 2.807 (19), 2.765 (5
1), 2.724 (53), 2.645 (14), 2.
509 (11), 2.472 (11), 2.375 (1
0), 2.276 (21), 2.189 (9), 2.1
08 (9), 1.91 (7), 1.906 (4), 1.
839 (8), L-ascorbic acid-2-phosphate
Excluding sodium salt crystals] .
JP2000050913A 1989-08-24 2000-02-28 Crystals of L-ascorbic acid-2-phosphate sodium salt Expired - Lifetime JP3378847B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000050913A JP3378847B2 (en) 1989-08-24 2000-02-28 Crystals of L-ascorbic acid-2-phosphate sodium salt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13153698A JP3117949B2 (en) 1989-08-24 1998-05-14 Crystals of L-ascorbic acid-2-phosphate sodium salt
JP2000050913A JP3378847B2 (en) 1989-08-24 2000-02-28 Crystals of L-ascorbic acid-2-phosphate sodium salt

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP13153698A Division JP3117949B2 (en) 1989-08-24 1998-05-14 Crystals of L-ascorbic acid-2-phosphate sodium salt

Publications (2)

Publication Number Publication Date
JP2000309596A JP2000309596A (en) 2000-11-07
JP3378847B2 true JP3378847B2 (en) 2003-02-17

Family

ID=26466357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000050913A Expired - Lifetime JP3378847B2 (en) 1989-08-24 2000-02-28 Crystals of L-ascorbic acid-2-phosphate sodium salt

Country Status (1)

Country Link
JP (1) JP3378847B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299912B1 (en) 1999-04-23 2001-10-09 Showa Denko Kabushiki Kaisha Preparation for administration to animals and feeding method thereof
CN106397486A (en) * 2016-08-31 2017-02-15 安徽天寅生物技术有限公司 Preparation method of high purity L-ascorbic acid-2-sodium phosphate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"BIOCHEMICAL MEDICINE"1978,第19巻,P.118〜126

Also Published As

Publication number Publication date
JP2000309596A (en) 2000-11-07

Similar Documents

Publication Publication Date Title
RU2041234C1 (en) CRYSTALLINE 2-O-α-D-GLUCOPYRANOZYL-L-ASCORBIC ACID AND METHOD FOR ITS PRODUCTION
US4136101A (en) Process for preparing dialkyl (p-aminobenzoyl) glutamates
US20180305388A1 (en) Crystal of 6'-sialyllactose sodium salt, and process for producing same
US6121464A (en) Preparation of salts of ascorbyl 2-phosphoric esters
JPS59130888A (en) Crystalline cephem-acid addition salt and manufacture
FI75571C (en) FRAMSTAELLNINGSFOERFARANDE FOER SYNNERLIGEN KRISTALLINISKT SODIUMCEFOPERAZON.
JP3378847B2 (en) Crystals of L-ascorbic acid-2-phosphate sodium salt
JP3117949B2 (en) Crystals of L-ascorbic acid-2-phosphate sodium salt
JP2877366B2 (en) Method for producing crystalline L-ascorbic acid-2-phosphate sodium salt
US4515943A (en) Crystal of beta-nicotinamide-adenine-dinucleotide and process for preparing the same
US6875891B2 (en) Process for preparing highly water soluble double salts of hydroxycitric acid particularly alkali and alkaline earth metal double salts
AU2012265238B2 (en) Crystallization of epirubicin hydrochloride
JPH02174789A (en) Preparation of riboflavin-4', 5'-cyclophosphoric ester chloride and riboflavin-5'-phosphate(5'-fmn) or sodium salt thereof
CA1122974A (en) Process for crystalline sodium cefamandole
JP4200593B2 (en) Crystalline L-ascorbic acid-2-phosphate sodium salt and process for producing the same
JP3750160B2 (en) Amorphous L-ascorbic acid-2-phosphate ester sodium salt and method for producing the same
US6271397B1 (en) L-ascorbic acid-2-phosphoric acid potassium crystal and method for producing the same
CN109734726B (en) Refining method of cefixime trihydrate crystals
EP0962461B1 (en) Crystalline potassium salt of L-ascorbic acid-2-phosphoric acid and method for producting the same
WO2008099413A2 (en) High purity (-) hydroxycitric acid metal salt derivatives and method of preparation of the same
KR830002685B1 (en) Process for preparing -(para-chlorophenoxy)-isobutyryl-aminobenzyl pneicillanic acid & its salt
JP2018039755A (en) Production method of 2 alpha-methyl-2 beta-(1,2,3-triazole-1-yl)-methyl penam-3 alpha-carboxylic acid 1,1-dioxide-sodium hydrate crystal
HU179752B (en) Process for preparing s-methyl-methionine-sulphonium chloride
JPH07165702A (en) Method for isolating natural type abscisic acid
EP1072605A1 (en) Process for producing ascorbic acid-2-phosphoric ester salts

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20010807

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081206

Year of fee payment: 6

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081206

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091206

Year of fee payment: 7

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091206

Year of fee payment: 7